Real consulting engagements delivering measurable results for pharmaceutical, biotech, and life sciences organizations. Every engagement includes outcome metrics and forward-looking forecasts.
20+
Consulting Engagements
5
Service Areas
8+
Therapeutic Areas
$15B+
Markets Informed
Consulting engagements with measurable client outcomes
Mid-sized biopharma company with 25+ pipeline assets in oncology
Challenge
A mid-sized biopharma with 25+ oncology pipeline assets lacked a systematic framework for portfolio prioritization. Investment decisions were made reactively, leading to resource misallocation and delayed termination of high-risk programs.
Forecast
Reallocated capital into higher-probability assets, projected to increase portfolio NPV by 22% over 3 years based on risk-adjusted modeling.
Specialty pharmaceutical company entering rare disease therapeutics
Challenge
A specialty pharma company planned to enter the rare disease space but lacked clarity on which indications offered the best opportunity. They needed disease burden analysis, treatment landscape mapping, and competitive intelligence across 15+ rare indications.
Forecast
Combined addressable market across 5 prioritized rare disease indications projected to reach $2.3B by 2031, driven by orphan drug pricing and unmet need.
Emerging pharma company launching first commercial product
Challenge
An emerging pharma company launching their first commercial oncology product needed a comprehensive market access and pricing strategy across 15 markets. They had no prior pricing experience and faced complex payer landscapes.
Forecast
Value-based pricing and optimized payer engagement projected to increase net revenue by 15% over 3 years vs. benchmark launch performance.
Mid-sized pharma launching next-generation diabetes therapy
Challenge
A mid-sized pharma company launching a next-generation diabetes therapy needed a comprehensive commercial excellence program. Their sales force lacked launch experience and competitive positioning was unclear against 12 established products.
Forecast
Launch excellence program projected to achieve 8.5% market share in year 1, exceeding benchmark of 5-6% for comparable diabetes launches.
Top-20 pharma company with established cardiovascular portfolio
Challenge
A top-20 pharma company with an established cardiovascular portfolio needed an emerging markets expansion strategy across 8 countries in Asia-Pacific and Latin America. They lacked local market intelligence and partnership frameworks.
Forecast
Phased entry into 8 emerging markets projected to generate $340M cumulative revenue over 5 years, representing 12% of global portfolio revenue.
Mid-cap pharma company seeking next stage of growth
Challenge
A mid-cap pharma company with $2B revenue faced a growth plateau with 3 products approaching loss-of-exclusivity. They needed a corporate growth strategy covering portfolio diversification, BD&A targets, and geographic expansion.
Forecast
Integrated growth strategy projected to achieve 12% CAGR over 5 years, driven by BD&A, geographic expansion, and portfolio diversification.
Pharma company evaluating biosimilar development portfolio
Challenge
A pharma company needed to evaluate 10 biologics for biosimilar development potential. They lacked comprehensive market analysis covering patent expiry, market size evolution, competitive biosimilar pipeline, and pricing erosion projections.
Forecast
4 prioritized biosimilar targets projected to generate $950M cumulative revenue over 7 years, with peak year revenue of $280M.
Consulting engagements with measurable client outcomes
Biopharma company with Phase II cardiovascular asset
Challenge
A biopharma company with a Phase II cardiovascular asset needed to benchmark their trial design against 40+ competing programs. They lacked visibility into endpoint selection, enrollment timelines, and competitive positioning.
Forecast
Optimized trial design and site selection projected to reduce time-to-readout by 4 months, enabling earlier regulatory submission and market entry.
Vaccine manufacturer modernizing clinical development
Challenge
A vaccine manufacturer needed to modernize their clinical development process with decentralized trial capabilities. They faced slow enrollment, limited patient diversity, and outdated data collection methods across 20+ trial sites.
Forecast
Decentralized trial implementation projected to reduce development costs by 22% over 3 years through faster enrollment, reduced site visits, and improved data quality.
Pharma company evaluating oncology therapy area expansion
Challenge
A pharma company with 2 approved oncology products needed a comprehensive therapy area analysis to guide expansion into 5 additional oncology indications. They lacked disease-level intelligence across treatment landscapes, emerging therapies, and unmet needs.
Forecast
Expansion into 3 prioritized oncology indications projected to add $4.2B in addressable market over 7 years, driven by high unmet need and favorable competitive dynamics.
Consulting engagements with measurable client outcomes
Biotech company with first-in-class neurology therapeutic
Challenge
A biotech company with a first-in-class neurology therapeutic needed a regulatory strategy across FDA, EMA, and PMDA. They lacked clarity on accelerated approval pathways, orphan drug designation potential, and comparative regulatory requirements.
Forecast
Accelerated approval pathway and orphan drug designation projected to enable market entry 8 months earlier than standard pathway, representing $120M+ in additional revenue.
Gene therapy company preparing for first commercial launch
Challenge
A gene therapy company preparing for their first commercial launch needed a comprehensive pricing and HEOR strategy. They faced unprecedented pricing challenges with a one-time therapy and uncertain payer willingness-to-pay.
Forecast
Value-based pricing with outcomes-based agreements projected to achieve $2.1M net revenue per patient, balancing access sustainability with innovation reward.
Global pharma company with operations in 40+ countries
Challenge
A global pharma company with operations in 40+ countries needed an enterprise risk management and compliance framework. They faced fragmented risk reporting, inconsistent compliance standards, and growing regulatory scrutiny across markets.
Forecast
Unified GRC framework projected to avoid $12M in compliance-related costs over 3 years through standardized processes, reduced audit findings, and prevented regulatory actions.
Consulting engagements with measurable client outcomes
Top-10 pharma company launching a novel immunology therapy
Challenge
A top-10 pharma company preparing for an immunology launch had an outdated KOL list with limited influence mapping. They needed to identify, profile, and engage 200+ KOLs across 12 markets with a data-driven approach.
Forecast
Data-driven KOL engagement projected to improve launch uptake by 18% in first 2 years, based on benchmark performance across comparable immunology launches.
Biotech company preparing for rare disease product launch
Challenge
A biotech company preparing for a rare disease product launch had an underdeveloped medical affairs function. They needed a comprehensive medical strategy, publication plan, and MSL engagement framework to build scientific credibility.
Forecast
Integrated medical affairs strategy projected to increase physician awareness by 45% within 2 years of launch, based on benchmark rare disease launches.
Top-10 pharma company with chronic disease portfolio
Challenge
A top-10 pharma company with a chronic disease portfolio needed to embed patient-centricity across their development and commercial processes. They lacked patient journey maps, engagement metrics, and advocacy relationships.
Forecast
Patient-centric interventions projected to improve medication persistence and adherence by 15% within 2 years, representing $85M in retained revenue.
Dermatology-focused biotech launching psoriasis therapy
Challenge
A dermatology-focused biotech launching a psoriasis therapy needed primary research with 150+ physicians across 8 markets to understand prescribing behavior, treatment gaps, and competitive positioning.
Forecast
Data-driven launch messaging informed by primary research projected to achieve 35% prescriber conversion within 18 months, exceeding benchmark of 25%.
Consulting engagements with measurable client outcomes
Top-15 pharma company evaluating $800M acquisition target
Challenge
A top-15 pharma company was evaluating a $800M acquisition of a late-stage biotech with 3 assets. They needed commercial due diligence covering market sizing, competitive landscape, peak sales forecasting, and risk assessment.
Forecast
Combined risk-adjusted peak sales of $1.4B across 3 assets projected by year 7, with 70% probability-weighted confidence interval.
Generic pharma company developing biosimilar portfolio
Challenge
A generic pharma company developing a biosimilar portfolio needed comprehensive patent landscape analysis and freedom-to-operate assessment for 5 reference products. They faced complex patent thicket challenges and unclear launch timing.
Forecast
5 biosimilar products with confirmed launch windows represent $1.8B cumulative market opportunity over 5 years post-patent expiry.
Cell therapy company scaling to commercial manufacturing
Challenge
A cell therapy company transitioning to commercial manufacturing needed CDMO selection, supply chain design, and quality systems consulting. They faced complex logistics requirements and limited manufacturing experience.
Forecast
Optimized CDMO selection and supply chain design projected to save $28M in manufacturing costs over 5 years at commercial scale.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions and decisions into outcomes.